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Leishmaniasis, caused by infection with parasites of the Leishmania genus, affects millions
of individuals worldwide.This disease displays distinct clinical manifestations ranging from
self-healing skin lesions to severe tissue damage. The control of Leishmania infection is
dependent on cellular immune mechanisms, and evidence has shown that CD4 and CD8T
lymphocytes play different roles in the outcome of leishmaniasis. Although the presence of
CD4T cells is important for controlling parasite growth, the results in the literature suggest
that the inflammatory response elicited by these cells could contribute to the pathogene-
sis of lesions. However, recent studies on CD8 T lymphocytes show that these cells are
mainly involved in tissue damage through cytotoxic mechanisms. In this review, we focus
on the recent advances in the study of the human adaptive immunological response in the
pathogenesis of tegumentary leishmaniasis.
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Tegumentary leishmaniasis (TL) is transmitted by sand flies and is
caused by different species of Old and New World Leishmania. The
disease is characterized by a wide spectrum of clinical manifesta-
tions, including self-healing skin lesions, cutaneous leishmania-
sis (CL), disseminated leishmaniasis (DL), mucosal leishmaniasis
(ML), and diffuse cutaneous leishmaniasis (DCL) [reviewed in
Ref. (1)]. Host–parasite interactions can lead to a series of events,
culminating in the different forms of clinical manifestations. This
review will address the role of adaptive immunological responses
in the pathogenesis of TL.
A BRIEF SUMMARY OF INNATE IMMUNE RESPONSES IN
INFECTIONS CAUSED BY LEISHMANIA
In the early events after Leishmania infection, macrophages
are activated, leading to NO synthesis (2–6), ROS production,
and lysosomal enzyme activation (7, 8), which are responsible
for killing the parasite. In contrast, the alternative activation
of macrophages by TGF-β provides a favorable environment
for Leishmania proliferation (9). Indeed, alternatively activated
macrophages preferentially induce the arginase activity respon-
sible for parasite replication (10). Recently, the importance of
neutrophils in the first events after Leishmania infection was
demonstrated. Using intravital microscopy, Peters et al. showed
these cells are rapidly recruited to the infection site and are respon-
sible for phagocytosis of the parasites (11). Furthermore, these cells
undergo apoptosis, and the parasites released in this process are
engulfed by macrophages, creating an anti-inflammatory environ-
ment that favors the establishment of infection. Our group also
observed that Leishmania amazonensis-infected macrophages in
the presence of resting apoptotic neutrophils produce TGF-β and
PGE-2, leading to parasite replication. Conversely, the presence of
necrotic neutrophils induces activation in infected macrophages,
with a decrease in the number of parasites phagocytosed by
macrophages (12). Human neutrophils were found to be activated
by L. amazonensis via LTB-4 production, which promotes neu-
trophil degranulation and the killing of parasites (13). In addition,
the release of neutrophil-derived extracellular DNA-containing
antimicrobial peptides is an important neutrophil function that
contributes to parasite killing (14, 15).
Dendritic cells (DCs) are critical for the initiation of an effec-
tive immune response against Leishmania. In the murine model of
Leishmania major, DC infection leads to cell activation, which up-
regulates costimulatory molecules, such as MHC II, CD80, and
CD86, and the release of IL-12, antigen presentation and T cell
priming (16, 17). Some reports have shown that infection with
different species of Leishmania parasites does not lead to changes
in the activations markers on DCs (18, 19). For instance, the infec-
tion of DCs by Leishmania braziliensis inhibits the up-regulation
of activation markers and antigen presentation, whereas unin-
fected cells are able to up-regulate MHC class II and costimulatory
molecules, inducing T cell activation (20). It was suggested that
these DCs in L. braziliensis infection lead to T cell activation, with
infected DCs contributing to parasite control through enhanced
TNF-α production.
In human leishmaniasis, NK cells are found to accumulate
rapidly at the inoculation site after Leishmania parasite invasion
www.frontiersin.org September 2014 | Volume 2 | Article 165 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
da Silva Santos and Brodskyn T cells in cutaneous leishmaniasis
(21). These cells are an important source of interferon (IFN)-γ,
which elicits microbicidal activity by macrophages. The protec-
tive role of NK cells in human leishmaniasis can be evidenced by
the recruitment of NK cells into the lesions of DCL patients who
respond to treatment (22, 23).
IMMUNE RESPONSES MEDIATED BY CD4 T CELLS IN
HUMAN CUTANEOUS LEISHMANIASIS
The cellular immune responses in leishmaniasis have been exten-
sively studied in mouse models, mainly using L. major infection.
Susceptible mice (BALB/c) develop progressive lesions, with a
predominance of the Th2 response, leading to the production
of anti-inflammatory cytokines, such as IL-4, IL-5, and IL-13.
Resistant mice infected by L. major display small lesions with
few parasites and a predominance of IFN-γ, TNF-α, and IL-2
cytokines, characteristic of a Th1 response. These latter cytokines
activate leishmanicidal mechanisms in infected macrophages, with
high ROS and NO production, leading to parasite killing (24).
In human beings, the immune response has an essential role
in pathogenesis, and it is not possible to observe Th1 and Th2
polarization. The cytokine profiles produced by T cells are asso-
ciated with the healing process (25–27) or with the development
of disease (28–30), as well as protective mechanisms (31). The
unresponsive pole of the disease observed in DCL is character-
ized by the high production of anti-inflammatory cytokines, such
as IL-10, IL-4, and IL-2, but there is no IFN-γ production upon
in vitro stimulus with Leishmania antigens (28). However, in ML,
the responsive pole of the disease, the cells from patients display
an exacerbated immune response (32) with a positive DTH (33–
35). There is some evidence that the tissue destruction observed
in LCL and ML is related to the immune response rather than to
the parasites present in the lesions, the number of which is very
low [reviewed in Ref. (1)].
Cells from ML patients stimulated in vitro with Leishma-
nia antigens secrete higher concentrations of pro-inflammatory
cytokines, such as TNF-α and IFN-γ, compared to cells from CL
patients (32). These cytokines are also present in the lesions of ML
patients (34), and TNF-α levels decrease following treatment. The
immune response in CL patients reveals a mixture of cytokines,
with the presence of anti- and pro-inflammatory cytokines in tis-
sues. CD4 T cells are the major source of IFN-γ (36, 37), and
this cytokine, as well as TNF-α, controls parasite multiplication
during the early phases of Leishmania infection. Regardless, these
cytokines also mediate the tissue damage (30). CD4 T cells at
the site of skin lesions were found to be the key producers of
IFN-γ upon restimulation in vitro and were capable of activating
macrophages for the killing of intracellular parasites. Unlike CD8
T cells, CD4 T cells were reported not to be involved in the cytoly-
sis of infected target cells. Therefore, no correlation between CD4
T cells and lesion size/immunopathology was found (38).
In CL patients, TNF-α is produced by different types of cells,
including lymphocytes and macrophages (16). Recently, a positive
correlation between ulcer size at the time of the first evalua-
tion and TNF-α levels was observed, supporting the use of TNF
inhibitors combined with standard therapy to improve recov-
ery time in CL patients with severe lesions (39). The treatment
of leishmaniasis patients with pentoxifylline associated with a
pentavalent antimonial decreased the recovery time in CL and
ML patients, even in those who were refractory to conventional
treatment (40, 41).
IL-10 is also produced by CL patients and is responsible for
down-regulating inflammatory responses, mainly those induced
by IFN-γ (42–44). IL-10 is produced by a variety of cells, includ-
ing macrophages, regulatory T (Treg) cells, Th1 cells, and CD8
T cells. The presence of Treg cells (natural and inducible) in the
lesions from CL patients as well as IL-10 and TGF-β production
has already been described. These cytokines are responsible for
the control of the immune response in CL patients but also for the
pathology of disease, deactivating the mechanisms of macrophage
killing and leading to parasite persistence (45, 46). A down-
regulation of IL-10 receptor was demonstrated in lesions from
ML patients, which can partly explain the lack of IL-10 response
and the absence of inflammatory process down-regulation (34).
More recently described cytokines are also observed in TL
patients. IL-27, a cytokine with close structural and functional
similarity to the IL-6/IL-12 family, is also expressed at high levels
in the peripheral blood and tissues of ML and CL patients. Despite
the induction of Th1 differentiation during the first steps of the
immune response, IL-27 has been shown to promote an attenua-
tion of inflammatory responses, improving IL-10 production by
Th1 CD4 T cells (47–49). This function precludes inflammation
and subsequent tissue damage in the late phase of the immune
response. However, Oliveira et al. showed that the addition by IL-
27 of PBMCs from CL and ML patients did not enhance IL-10
production by these cells, suggesting that IL-27 did not have an
effect on regulating the strong inflammatory response observed in
human CL patients (50).
To better understand the pathogenesis of TL, Carvalho’ group
has studied SC patients, who display a positive DTH response
against Leishmania antigens but do not exhibit any lesions. These
patients are infected by L. braziliensis, but their immune responses
are protective against the development of disease. Individuals with
SC L. braziliensis infection present cellular immune responses that
are less intense than those observed in CL or ML and produce
significantly lower levels of IFN-γ and TNF-α than CL patients
(51). More recently, Novoa et al. reported a stronger Th1 response
in CL patients than in SC individuals, though the levels of IL-
10 were higher in the latter patients than in the former patients
(52). Although the mechanisms by which SC individuals control
parasite growth are unknown, innate immune responses could
play an important role in this control, with the participation of
neutrophils, macrophages, and NK cells [reviewed in Ref. (53)].
More recently, the role of TH17 cells in the pathogenesis of TL
has been discussed. Although the presence of these cells has been
associated with the pathology of many autoimmune diseases, their
role in leishmaniasis is not clear. The presence of Th17 cells and
neutrophil recruitment are observed in the ML lesions of patients,
in areas of necrosis and also with MMP-9 participation (54, 55).
However, in CL patients, IL-17 is present in the supernatant of
cells stimulated by Leishmania antigens; nonetheless, its role in
the pathology of the disease is not well established (55). There-
fore, different subsets of CD4 T cells not only produce cytokines
responsible for the control of parasite proliferation but also con-
tribute to the development of inflammatory responses. The lack
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of down-regulation of this inflammation could be responsible
for the pathogenesis, as is observed in ML patients. However, as
observed in SC patients, the balance of pro- and anti-inflammatory
cytokines contributes to protection against the disease. In addition,
there is recent evidence of the role played by CD8 T cells in the
pathogenesis of the disease.
CD8 T CELL IMMUNE RESPONSE IN LEISHMANIA sp
INFECTION
CD8 T cells provide immunity against a wide variety of pathogens,
including viral, bacterial, and protozoal infections. These cells are
generally considered to contribute to immunity and protection
against Leishmania.
Muller et al. showed that the initial transitory depletion of CD4
T cells in mice susceptible to L. major infection causes them to be
resistant to infection by the parasite via a mechanism that is depen-
dent on an environment enriched by CD8 T cells (56). The authors
demonstrated that CD8 T cells play an important role in protec-
tion after re-infection, producing high amounts of IFN-γ (56).
CD8 T cells from healed mice were able to transfer DTH responses
to naïve recipients (57) and also displayed cytotoxic activity (58).
Contradicting these findings, it was demonstrated that CD8 T cells
were not essential to the primary protective response to L. major-
infected mice because β2-microgobulin-deficient or Cd8-/- mice
maintained their capacity to resolve the primary infection (59, 60).
In 2002, using an intradermal model of infection with low number
of parasites (~100), Belkaid et al. demonstrated that CD8 T cells
are important for the control of primary infections in resistant
mice infected by L. major (61). In this low-infection model, CD8
T cells producing IFN-γ promoted the change from the early Th2
response toward a Th1 response (62).
CD8 T cells producing IFN-γ are also important for the mod-
ulation of the CD4 T cell response. Although the depletion of
CD8 T cells did not interfere with the proliferative ability of CD4
T cells, a reduction in the percentage of CD4 T cells producing
IFN-γ was observed, an effect that was associated with an increase
in parasite load in mice, suggesting an interaction between CD4
and CD8 T cells (63). In human leishmaniasis, important roles
of CD8 T cells in the healing process through IFN-γ production
(25, 27, 64) and in resistance to the infection have been described
(31). However, few reports have evaluated the role of these cells in
the primary infection. Our group used an experimental approach
called in vitro priming, in which cells from healthy volunteers
were stimulated by L. amazonensis and cultured for 96 h. We
observed that CD8 T cells were the first to express activation mark-
ers and were important for Th1 activation (65). In infection by L.
braziliensis, an increase in the number of CD8 T cells reactive
to Leishmania antigens during the healing process was observed
(66); large proportion of these cells could also be observed at the
inflammatory site of the infection (67). A higher amount of CD8 T
cells producing IFN-γ was also associated with protective immu-
nity in infection by L. major (68). However, the presence of CD8
T cells showing functional exhaustion has been observed in DCL
patients: these cells produce a low level of IFN-γ upon stimula-
tion compared to CL patients (69). Therefore, these cells would
be important in the development of acquired immunity to the
infection.
CD8 T cells are also able to produce IL-10. Bourreau et al.
analyzed PBMCs from unexposed naïve subjects and CL patients
in response to Leishmania guyanensis stimulation and demon-
strated that IL-10 was produced by the cells from both groups
when TGF-β was neutralized. An analysis of the phenotype of
IL-10-producing cells in naïve subjects clearly showed that they
are memory cells characterized as CD45RA-CD8 T cells (70) and
appear to be effective during human infection.
Despite the apparent protective role of CD8 T cells follow-
ing infection with the intracellular Leishmania parasite, these cells
have been paradoxically linked to immunopathological responses.
Our group implicated CD8 T cells in the pathogenesis of ML (71,
72). The presence of cytolytic CD8 T cells has also been demon-
strated in the lesions from CL patients. Machado et al. observed
the presence of CD8 T cells and a strong expression of a molecule
associated with cytotoxic activity (TIA-1) in the inflammatory site
of infection (73). Moreover, Faria et al. showed the recruitment
of CD8 T cells expressing granzyme A to lesions of CL patients,
and the expression of this protease was positively correlated with
lesion progression in these patients (74). Our group found similar
results, showing the recruitment of CD8 T cells to lesion sites in
CL patients. These cells expressed granzyme B and CD107a and
were positively correlated with the necrosis intensity and lesion
size observed in these patients (38). More recently, Novais et al.
showed that disease progression and metastasis in L. brazilien-
sis-infected mice were directly associated with the presence of
CD8 T cells. The authors demonstrated that perforin-expressing
CD8 T cells were required to mediate immunopathology and that
this was independent of the parasite burden (75). In human CL
caused by L. major and Leishmania mexicana, granzyme B activ-
ity was also associated with a good prognosis (76, 77). In these
studies, the in vitro cytotoxicity observed in the co-culture of Leish-
mania infected macrophages with peripheral blood lymphocytes
appeared to be mediated by granzyme B. However, the release
of granzyme B does not appear to participate in the control of
parasite growth (38, 75). Recently, Crosby et al. demonstrated
the participation of bystander memory CD8 T cells expressing
NKG2D in leishmanial lesion progression. The authors showed
that mice infected previously by viral or bacterial pathogens and
challenged by L. major developed significantly larger lesions, with
an increased number of NKG2D-positive CD8 T cells; however,
the immunopathology was not associated with any changes in the
parasite burden (78). In fact, non-Leishmania-specific CD8 T cells
are found within human leishmanial lesions (79). Taken together,
these studies highlight the harmful role played by cytolytic CD8 T
cells in contributing to tissue injury. These data are summarized
in Table 1.
CONCLUDING REMARKS
Studies in the literature have shown the important role played by
CD4 T cells in protection against human leishmaniasis by pro-
ducing cytokines able to activate the macrophages that kill the
parasites. However, a strong inflammatory response contributes
to lesion development and the immunopathogenesis of the dis-
ease. More recently, the role displayed by CD8 T cells has been
better characterized, mainly with regard to the infection caused by
L. braziliensis in human beings and mice. These cells contribute to
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Table 1 | Protective vs pathological function of CD8T cells.
PROTECTIVE ROLE OF CD8T CELLS
Depletion of CD4 T cells in mice makes them resistant to infection, a mechanism dependent on CD8 T cells (56)
Transfer of CD8 T cells from healed mice is able to induce the DTH response in naïve recipients (57)
Infection with a low number of parasites elicits a primary immune response by CD8 T cells (61)
IFN-γ produced by CD8 T cells promotes the change from a Th2 to a Th1 response (62)
CD8 T cells are important in the healing process and in resistance to the infection in human beings (25, 27, 31, 64, 66)
In vitro priming experiments with human cells show that CD8 T cells produce IFN-γ and drive Th1 differentiation (65)
CD8 T cells in infection by L. mexicana and L. major are related to a good prognosis in human beings (77)
CD8 T cells produce IFN-γ in L. major infection (68)
PATHOLOGICAL ROLE OF CD8T CELLS
CD8 T cells are not essential for the primary response to L. major in mice (59, 60)
Cytotoxic cells are associated with pathogenesis in mucosal leishmaniasis (71, 72)
CD8 T cells displaying cytotoxic activity are found at the inflammatory site of infection in human beings (73)
CD8 T cells express granzyme A in the lesions of CL patients (74)
CD8 T cells expressing granzyme B and CD107a, characteristic of CTL, are related to tissue damage in the lesions of CL patients (38)
Disease progression and metastasis in L. braziliensis-infected mice are related to cytotoxic CD8 T cells. (75)
the differentiation of Th1 responses in the early events of par-
asite infection, whereas they contribute to lesion development
after establishment of the infection. Their presence and cytotoxic
activity are directly correlated to the lesion size and the pres-
ence of necrosis. Interestingly, after cure of the disease, CD8 T
cells can produce IFN-γ and are also correlated with the healing
process.
The understanding of the immunopathological mechanisms
displayed by CD4 and CD8 T cells is essential for the design of
new therapeutic and vaccine strategies in human TL.
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